INPP4B: the New Kid on the PI3K Block

Irina U. Agoulnik; Myles C. Hodgson; Wayne A. Bowden; Michael M. Ittmann

doi:10.18632/oncotarget.260

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

INPP4B: the New Kid on the PI3K Block

Irina U. Agoulnik _, Myles C. Hodgson, Wayne A. Bowden and Michael M. Ittmann

PDF | HTML | How to cite

Oncotarget. 2011; 2:321-328. https://doi.org/10.18632/oncotarget.260

Metrics: PDF 4696 views | HTML 5361 views | ?

Abstract

Irina U. Agoulnik¹, Myles C. Hodgson¹, Wayne A. Bowden¹, Michael M. Ittmann²

¹ Herbert Wertheim College of Medicine, Miami, FL

² Baylor College of Medicine, Houston, TX

Keywords: cancer, PI3K, phosphatase, PTEN, tumor suppressor, oncoprotein, oncotarget

Received: April 6, 2011; Accepted: April 10, 2011; Published: April 10, 2011;

Correspondence:

Irina Agoulnik, e-mail:

Abstract

Dysregulation of phosphatidyl inositol signaling occurs in many cancers and other disorders. The lipid and protein phosphatase, PTEN (Phosphatase and Tensin homology protein on chromosome 10), is a known tumor suppressor whose function is frequently lost in various malignancies due to mutations in the coding region or genomic deletions. Recently, another lipid phosphatase, Inositol Polyphosphate 4-phosphatase type II (INPP4B), has emerged as a potential tumor suppressor in prostate, breast, and ovarian cancers and possibly in leukemia. We will review its structure and function, crosstalk with androgen receptor signaling, and regulation of INPP4B expression, as well as existing data about its role in cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 260

Publication Alerts

Research Perspectives:

INPP4B: the New Kid on the PI3K Block

Abstract